Novo Nordisk triples APAS® installed base as validation phase begins
Clever Culture Systems (ASX: CC5) has received a purchase order from Novo Nordisk for two additional APAS® Independence instruments, lifting the pharmaceutical group’s installed base to three. The order also covers development of a custom integration with Novo Nordisk’s global Laboratory Information Management System (LIMS).
The purchase follows a successful 12-month evaluation and marks Novo Nordisk’s move into formal global validation. For CCS, it stands as early proof of its “Land and Expand” strategy targeting major global pharmaceutical manufacturers.
When big ASX news breaks, our subscribers know first
What the Novo Nordisk order includes
The purchase order comprises two distinct components, each with a separate role in Novo Nordisk’s adoption pathway.
-
Two additional APAS® Independence instruments installed at a single site in Denmark to complete a formal global validation of the technology. The sales price for each instrument is consistent with previously disclosed targeted pricing.
-
An advanced interface between Novo Nordisk’s global LIMS and APAS®, enabling bi-directional communication between the two systems for more intelligent sorting of environmental monitoring samples, ultimately driving greater value from the instrument.
Successful completion of the validation will allow the instruments to transition into routine laboratory use supporting the regulatory required Good Manufacturing Practice (GMP). CCS describes this as the final technology performance milestone required by Novo Nordisk ahead of potential broader deployment. The company has not confirmed deployment beyond the validation stage.
Brent Barnes, CCS CEO and Managing Director
“This order from Novo Nordisk is a further demonstration of the APAS® technology performance and provides evidence of our long-stated Land and Expand strategy targeting major global pharmaceutical manufacturers. Sterile drug manufacturing companies rightly undergo a rigorous process when introducing new technologies into their manufacturing network. Patient safety, data integrity and regulatory compliance is critical, and we have designed APAS® from the outset to meet these requirements and to integrate into our customers’ systems.”
What is APAS® Independence and why it matters
APAS® Independence uses artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. According to CCS, the technology “remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading.”
In pharmaceutical manufacturing, the system is used to read environmental monitoring culture plates, a routine quality control task in sterile drug production.
Why does the slow pace of adoption matter to investors? Sterile drug manufacturers apply rigorous, methodical processes before introducing new technology, prioritising patient safety, data integrity and regulatory compliance. Clearing validation with a customer such as Novo Nordisk represents a high barrier. Once passed, it supports the potential for recurring, multi-site deployment across a manufacturer’s global network.
Inside the Land and Expand strategy driving FY27 growth
Novo Nordisk purchased its first APAS® Independence instrument in July 2025 to support an initial global evaluation of the technology to determine potential suitability for use across its manufacturing network. Following successful completion of that evaluation, the two additional instruments now ordered will support a formal validation.
That progression illustrates the “Land and Expand” strategy CCS is pursuing across large multi-site global pharmaceutical manufacturers. The company reports it has now installed APAS® Independence with 8 global manufacturers, each progressing through different stages of evaluation, validation and deployment. While each customer follows its own processes and timelines, CCS is focused on advancing them towards routine GMP use and broader rollout.
The expansion opportunity across 8 global customers
CCS has published a “Land & Expand playbook” graphic summarising the current status and expansion opportunity across this multi-site pharmaceutical cohort. The company explicitly notes the graphic does not represent CCS’s total customer base.
At the cohort level, the graphic outlines an expansion opportunity of approximately ~100 APAS instruments, a ~$51M CAPEX opportunity and ~$10M ARR on a SaaS/recurring basis. The figures are drawn from the company’s graphic.
| Customer | Instruments Purchased | Stage | Segment | Notes |
|---|---|---|---|---|
| AstraZeneca | 12 | Deployment | Global pharma customer | 12 instruments purchased across global sites |
| Novo Nordisk | 3 | Validation phase commenced | Global pharma customer | Expand |
| Bristol Myers Squibb | Not disclosed | Not disclosed | Global pharma customer | Part of cohort |
| Pfizer | Not disclosed | Not disclosed | Global pharma customer | Part of cohort |
| Boehringer Ingelheim | Not disclosed | Not disclosed | Global pharma customer | Part of cohort |
| CSL Behring | Not disclosed | Not disclosed | Global pharma customer | Part of cohort |
| Thermo Fisher (Patheon) | Not disclosed | Not disclosed | Global pharma CDMO customer | Part of cohort |
| Confidential | Not disclosed | Not disclosed | Global pharma customer | Part of cohort |
The cohort-level figures above are sourced from the company’s graphic and should be read as an indicative opportunity rather than confirmed sales.
The CSL Behring evaluation order, structured as a 5-year all-inclusive lease at CSL’s Broadmeadows facility, illustrates how different customers are entering the cohort on varied commercial terms while pursuing the same potential multi-site standardisation outcome.
Why the step-change in FY27 sales matters for investors
CCS restates expectations of a step-change increase in sales commencing FY27, largely driven by sales expansion with existing customers plus new customer opportunities converting to sales.
Brent Barnes, CCS CEO and Managing Director
“Importantly, we are now seeing the early benefits of the customer base we have established over the past two years. As these customers progress from evaluation and initial adoption towards broader deployment, we expect expansion from existing customers to become the major driver of a step-change in sales from FY27 and beyond.”
The recurring SaaS/ARR component highlighted in the company’s cohort opportunity signals a potential shift from one-off hardware sales towards recurring revenue as customers move to routine deployment. For investors, this points to a possible change in revenue quality over time, though the pace remains dependent on individual customer timelines.
Beyond the pharmaceutical segment, Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe. With eight global manufacturers now engaged at various stages, CCS’s forward momentum rests on converting evaluation and validation activity into routine, multi-site deployment from FY27.
CCS’s FY26 quarterly update provides further context on the financial position underpinning that transition, including cash at 30 June 2026, known near-term inflows, and the short-term debt facility due for repayment by 31 December 2026.
Ready to Learn More About CCS’s Land and Expand Strategy?
With Novo Nordisk now entering formal global validation and a cohort of eight major manufacturers representing a ~$51M CAPEX opportunity, the APAS® Independence platform is progressing towards the step-change in sales CCS anticipates from FY27.
Explore the full details of the APAS® technology, customer pipeline, and growth outlook by visiting the Clever Culture Systems investor centre for the latest updates and announcements.